Good Efficacy, Safety With Linagliptin

ADA 2011 — SAN DIEGO — The recently approved DPP-4 inhibitor linagliptin (Tradjenta) provided comparable control in type 2 diabetes to glimepiride (Amaryl) when added to metformin and cut the risk of cardiovascular events in half, researchers said here.


< Back to Listings